A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Phase 1/2 Completed 102 enrolled Glycyx Therapeutics Theravance Biopharma · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TD-1211 in healthy subjects and activity in subjects with opioid-induced constipation (OIC).

Timeline

Start: 2010-01
Primary completion: 2010-10
Completion: 2010-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	axelopran	Small molecule	—	Oral

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Summary

Timeline

Drugs

Indications